Corrigendum to "Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years' Follow-up of DEFINE, CONFIRM, and ENDORSE"
Journal: 2022/February - Therapeutic Advances in Neurological Disorders
Abstract:
[This corrects the article DOI: 10.1177/1756286420915005.].
Relations:
Content
Diseases
(1)
Chemicals
(1)
Similar articles
Articles by the same authors
Discussion board

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Gold R, Arnold DL, Bar-Or A et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ followup of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord 2020; 13: 1–17. doi: 10.1177/1756286420915005

In the above referenced article, in Figure 1 the number of patients in the PBO/DMF and DMF/DMF efficacy populations were reported incorrectly as n=501 and n=249, respectively. In fact, the n number for the PBO/DMF cohort should be n=249, and for DMF/DMF should be n=501. Figure 1 has been changed to reflect as given below:

An external file that holds a picture, illustration, etc.
Object name is 10.1177_1756286420968357-fig1.jpg

Patient populations for safety, efficacy, and lymphocyte analysis.

DMF, dimethyl fumarate; BID, twice daily; TID, three times daily; MRI, magnetic resonance imaging; PBO, placebo.

Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.